Delving into the Latest Updates on Mecasermin (Ipsen SA) with Synapse

Investigators are recruiting children for a clinical trial using the medication recombinant human IGF-1 (a.k.a. mecasermin or INCRELEX) to see if it improves the health of children with Rett syndrome (RTT). While IGF-1 is approved by the Food & Drug Administration (FDA) for certain use in children, it is considered an investigational drug in this trial because it has not previously been used to treat RTT. Information from this study will help determine if IGF-1 effectively treats RTT but will not necessarily lead to FDA approval of IGF-1 as a treatment for RTT.

Start Date01 Jan 2013

Sponsor / Collaborator

The Children's Hospital Corp.

[+1]

NCT01525901

/ CompletedPhase 2IIT

A Double-Blind Placebo-Controlled Crossover Trial of Insulin-Like Growth Factor-1 (IGF-1) in Children and Adolescents With 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)

The purpose of this study is to pilot the use of Insulin-Like Growth Factor-1 (IGF-1) treatment in 22q13 Deletion Syndrome (Phelan-McDermid Syndrome) caused by SHANK3 gene deficiency in order to evaluate safety, tolerability, and efficacy. IGF-1 is an injection under the skin that contains human IGF-1. IGF-1 is approved by the FDA under the brand name Increlex for the treatment of children with short stature due to primary IGF-1 deficiency. It is being used off-label in the current study and is not FDA approved, nor has it yet been studied in humans for the treatment of SHANK3 deficiency.

Start Date01 Feb 2012

Sponsor / Collaborator

Icahn School of Medicine at Mount Sinai

[+1]

NCT01207908

/ CompletedPhase 1/2IIT

IGF-1 Therapy and Muscle Function in Duchenne Muscular Dystrophy

The purpose of this study is to determine whether IGF-1 therapy improves or preserves muscle function in Duchenne Muscular Dystrophy (DMD).

Start Date01 Nov 2010

Sponsor / Collaborator

Children's Hospital & Medical Center

[+2]

100 Clinical Results associated with Mecasermin (Ipsen SA)

Login to view more data

100 Translational Medicine associated with Mecasermin (Ipsen SA)

Login to view more data

100 Patents (Medical) associated with Mecasermin (Ipsen SA)

Login to view more data

89

Literatures (Medical) associated with Mecasermin (Ipsen SA)

01 Jun 2024·International Journal of Biological Macromolecules

Injectable thermo-responsive Poloxamer hydrogel/methacrylate gelatin microgels stimulates bone regeneration through biomimetic programmed release of SDF-1a and IGF-1

Article

Author: Lei, Mingyuan ; Fu, Jinlang ; Shi, Zhanjun ; Tang, Zinan ; Chen, Rong ; Xie, Jiajun ; Xu, Yixin ; Chen, Yuhang ; Mai, Huaming ; Zhong, Qiang ; Cheng, Hao ; Wang, Jian ; Wang, Ding

Injectable hydrogels, offering adaptable drug delivery of growth factors (GFs), hold promise for treating bone defects. To optimize osteogenic efficacy, the release of GFs should mirror the natural bone healing. We developed an injectable thermo-responsive hydrogel/microgels platform for dual GF delivery for bone regeneration. Stromal cell-derived factor-1 alpha (SDF-1a) and the Methacrylate Gelatin (GelMA) microgels which encapsulated insulin-like growth factor-1 (IGF-1) loaded liposomes (Ls) were introduced into Poloxamer 407 (P407) hydrogel matrix. This system achieved the biomimetic release profile of SDF-1a and IGF-1, which covered the early stage from day 1 to 7 and the continuous stage from day 5 to 21, respectively. In vitro study confirmed the enhanced migration, osteogenic biomarker expression, and matrix mineralization of the bone marrow mesenchymal stem cells (BMSCs) co-cultivated with the dual GFs delivering hydrogel/microgels. Transcriptome sequencing revealed that the potential mechanism was associated with mitogen-activated protein kinase (MAPK) signaling activation and its downstream ribosomal protein S6 kinase 2 (RSK2) upregulation. In a critical-sized calvarial defect model in Sprague-Dawley (SD) rats, the injectable hydrogel/microgels system promoted significant bone regeneration. Collectively, our study suggested the current hydrogel/microgels system with the biomimetic release of SDF-1a and IGF-1 efficiently promoted bone regeneration, informing the future development of GF delivery systems intended for bone regeneration therapies.

21 Dec 2023·The Journal of Clinical Endocrinology & Metabolism

Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry

Article

Author: Ramon-Krauel, Marta ; Argente, Jesús ; Polak, Michel ; Sert, Caroline ; Bang, Peter ; Perrot, Valerie ; Bossowski, Artur ; Mazain, Sarah ; Maghnie, Mohamad ; Woelfle, Joachim

AbstractContextThe European Increlex® Growth Forum Database (Eu-IGFD) is an ongoing surveillance registry (NCT00903110) established to collect long-term safety and effectiveness data on the use of recombinant human insulin-like growth factor-1 (rhIGF-1, mecasermin, Increlex) for the treatment of children/adolescents with severe primary insulin-like growth factor-1 deficiency (SPIGFD).ObjectiveThis analysis of Eu-IGFD data aimed to identify the frequency and predictive factors for hypoglycemia adverse events (AEs) in children treated with rhIGF-1.MethodsData were collected from December 2008 to May 2021. Logistic regression was performed to identify predictive risk factors for treatment-induced hypoglycemia AEs. Odds ratios (ORs) are presented with 95% CIs for each factor.ResultsIn total, 306 patients were enrolled in the registry; 84.6% were diagnosed with SPIGFD. Patients who experienced ≥ 1 hypoglycemia AE (n = 80) compared with those with no hypoglycemia AEs (n = 224) had a lower mean age at treatment start (8.7 years vs 9.8 years), a more frequent diagnosis of Laron syndrome (27.5% vs 10.3%), and a history of hypoglycemia (18.8% vs 4.5%). Prior history of hypoglycemia (OR 0.25; 95% CI: [0.11; 0.61]; P = .002) and Laron syndrome diagnosis (OR 0.36; 95% CI: [0.18; 0.72]; P = .004) predicted future hypoglycemia AEs. Total hypoglycemia AEs per patient per treatment year was 0.11 and total serious hypoglycemia AEs per patient per treatment year was 0.01.ConclusionHypoglycemia occurs more frequently in patients with prior history of hypoglycemia and/or Laron syndrome compared with patients without these risk factors, and these patients should be carefully monitored for this AE throughout treatment.

01 Jun 2023·Molecular Neurobiology

Insulin-Like Growth Factor-1 Promotes Synaptogenesis Signaling, a Major Dysregulated Pathway in Malformation of Cortical Development, in a Rat Model

Article

Author: Yum, Mi-Sun ; Kim, Eun-Jin ; Kim, Min-Jee ; Kim, Kyunggon ; Lee, Minyoung ; Yeom, Jeonghun

Malformation of cortical development (MCD) is one of the main causes of intractable epilepsy in childhood. We explored a treatment based on molecular changes using an infant rat model of methylazoxymethanol (MAM)-induced MCD established by injecting MAM at gestational day 15. The offspring were sacrificed on postnatal day (P) 15 for proteomic analysis, which revealed significant downregulation in the synaptogenesis signaling pathway in the cortex of MCD rats. Recombinant human insulin-growth factor-1 (rhIGF-1) was injected from P12 to P14 twice daily and the effect of IGF1 on N-methyl-D-aspartate (NMDA)-induced spasms (15 mg/kg of NMDA, i.p.) was tested; the onset of P15 single spasm was significantly delayed (p = 0.002) and the number of spasms decreased (p < 0.001) in rhIGF1-pretreated rats (n = 17) compared to those in VEH-treated rats (n = 18). Electroencephalographic monitoring during spasms showed significantly reduced spectral entropy and event-related spectral dynamics of fast oscillation in rhIGF-1 treated rats. Magnetic resonance spectroscopy of the retrosplenial cortex showed decreased glutathione (GSH) (p = 0.039) and significant developmental changes in GSH, phosphocreatine (PCr), and total creatine (tCr) (p = 0.023, 0.042, 0.015, respectively) after rhIGF1 pretreatment. rhIGF1 pretreatment significantly upregulated expression of cortical synaptic proteins such as PSD95, AMPAR1, AMPAR4, NMDAR1, and NMDAR2A (p < 0.05). Thus, early rhIGF-1 treatment could promote synaptic protein expression, which was significantly downregulated by prenatal MAM exposure, and effectively suppress NMDA-induced spasms. Early IGF1 treatment should be further investigated as a therapeutic strategy in infants with MCD-related epilepsy.

22

News (Medical) associated with Mecasermin (Ipsen SA)

28 Apr 2025

·www.globenewswire.com

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another important milestone for Eton, and for the thousands of children impacted by diabetes insipidus. If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, providing the small, precise, and titratable doses required to treat pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long expressed a need for this product, and we’re pleased to be one step closer to bringing it to patients. Pre-launch commercial activities are already underway as we plan for a potential approval in the first quarter of 2026.” Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-600, which expires in 2044 and has additional patent applications under review. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. The company estimates that central diabetes insipidus impacts approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc.

NDA

28 Apr 2025

·ir.etonpharma.com

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) | Eton Pharmaceuticals, Inc.

News Release Details « Back to news Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another important milestone for Eton, and for the thousands of children impacted by diabetes insipidus. If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, providing the small, precise, and titratable doses required to treat pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long expressed a need for this product, and we’re pleased to be one step closer to bringing it to patients. Pre-launch commercial activities are already underway as we plan for a potential approval in the first quarter of 2026.” Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-600, which expires in 2044 and has additional patent applications under review. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. The company estimates that central diabetes insipidus impacts approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

NDA

02 Apr 2025

·pipelinereview.com

ESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatment

BARCELONA, Spain I April 1, 2025 I ESTEVE has signed a license and supply agreement with Eton Pharmaceuticals with global rights for Increlex®, except for USA. This biologic product, the first biologic in ESTEVE’s portfolio, is used for the long-term treatment of growth failure in patients aged 2 to 18 years due to a condition known as ‘severe primary insulin-like-growth-factor-1 deficiency’ (SPIGFD). Patients with this condition have low levels of the hormone insulin-like growth factor-1 or IGF-1, which is required for normal growth. 1 “As a rare disorder, patients suffering SPIGFD, often face difficulties associated with receiving a late correct diagnosis, with consequent delayed treatment initiation with limited access to appropriate therapy. This has a considerable impact on the physical health and quality of life of these patients. 2 The disease awareness and the multidisciplinary approach are critical to improve those people’s lives. This standard of care medicine is perfectly aligned with our strategy,focused on highly specialized treatments for high unmet medical and patient needs”, confirms José María Giménez Arnau, Chief Scientific & Medical Officer of ESTEVE. Increlex® was designated an ‘orphan medicine’ (a medicine used in rare diseases) in 2006. 1 It is approved by the U.S. Food and Drug Administration (FDA) 3 and European Medicines Agency (EMA) 1 and authorized in 40 territories. References About ESTEVE ESTEVE ( www.esteve.com ) is a global pharmaceutical company with a clear purpose: to improve people’s lives. Founded in 1929 and headquartered in Barcelona, ESTEVE has a strong international presence with pharmaceutical affiliates in Spain, Portugal, Italy, Germany, France, the UK, and the USA. ESTEVE is focused on delivering highly specialized treatments that address significant unmet medical needs in several therapeutic areas. In addition, to our innovative pharma business, we offer comprehensive Contract Manufacturing services (CMO), specializing in the production of Active Pharmaceutical Ingredients (APIs) through world-class facilities in Spain, Mexico, and China. ESTEVE’s strong commitment to its core values—people matter, transparency, and accountability—remains at the heart of everything it does. SOURCE: Esteve

License out/inOrphan DrugDrug Approval

100 Deals associated with Mecasermin (Ipsen SA)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Mecasermin (Ipsen SA)	H01AC03	DB01277

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Failure to Thrive	Canada	Ipsen Biopharmaceuticals, Inc.	17 Dec 2020
Primary insulin like growth factor-1 deficiency	Canada	Ipsen Biopharmaceuticals, Inc.	17 Dec 2020
Dwarfism	Australia	Ipsen SA	22 Nov 2019
Growth Disorders	United States	Ipsen Biopharmaceuticals, Inc.	30 Aug 2005
Growth hormone deficiency	United States	Ipsen Biopharmaceuticals, Inc.	30 Aug 2005
Insulin-Like Growth Factor I Deficiency	United States	Ipsen Biopharmaceuticals, Inc.	30 Aug 2005

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Crohn Disease	Phase 1	United States	Tercica, Inc.	01 Oct 2008
Failure to Thrive	Phase 1	United States	Ipsen SA	01 Mar 2004
Diabetes Mellitus	Phase 1	United States	Tercica, Inc.	-
Multiple Sclerosis	Phase 1	United States	Genentech, Inc.	-
Muscular Dystrophy, Duchenne	Discovery	United States	Ipsen SA	01 Nov 2010
Dwarfism	Discovery	United States	Ipsen SA	01 Jul 2005
Insulin-Like Growth Factor I Deficiency	Discovery	United States	Ipsen SA	01 Jul 2005
Failure to Thrive	Discovery	United States	Ipsen SA	01 Mar 2004
Primary insulin like growth factor-1 deficiency	Discovery	United States	Ipsen SA	01 Mar 2004
Laron Syndrome	Discovery	United States	Ipsen SA	20 May 1991

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00571727 (CTgov)	Phase 2/3	Laron Syndrome	92	Mecasermin	xndrylsatl(ivnhjqwhmv) = mlurwkqhdb rrgbjtktkw (kppztpyeas, bfsucvlcfa - faryjakkwu) View more	-	06 Jul 2023
ESPE2022	Not Applicable	insulin receptor gene	-	rhIGF-I	(icvgsugwcx) = blyizeyuco orutqzsnzy (byhtrzcpif ) View more	-	15 Sep 2022
ESPE2022	Not Applicable	insulin receptor gene	-	metreleptin	(cdnsmmnnbc) = pdymosmhjd etblzfesnl (beojqbhvrl ) View more	-	15 Sep 2022
NCT01525901 (CTgov)	Phase 2	Phelan-McDermid syndrome	19	Insulin-Like Growth Factor-1 (IGF-1) (Insulin-Like Growth Factor-1 (IGF-1))	usmuqtxrjk(kjveecqkrf) = udtfpdmzhv zgujmetehp (pmcwzraiki, byqxaxzord - nofrblzign) View more	-	12 May 2022
NCT01525901 (CTgov)	Phase 2	Phelan-McDermid syndrome	19	Normal Saline (Normal Saline)	usmuqtxrjk(kjveecqkrf) = fepzamxuyu zgujmetehp (pmcwzraiki, kgvugcidjc - ykmpbhyman) View more	-	12 May 2022
NCT01207908 (CTgov)	Phase 1/2	Muscular Dystrophy, Duchenne	44	IGF-1 (IGF-1)	gmlikcjkvs(hmotogvqtz) = fiebglksol tjbmoltxnc (hcjcscapjr, jizulmixck - awovvwaxcm) View more	-	20 Jan 2021
NCT01207908 (CTgov)	Phase 1/2	Muscular Dystrophy, Duchenne	44	steroid+Prednisone+Deflazacort (Standard Steroid Treatment Alone)	gmlikcjkvs(hmotogvqtz) = dizzsvgxpm tjbmoltxnc (hcjcscapjr, wtwjancjqs - pabrnoqvuz) View more	-	20 Jan 2021
ESPE2019	Not Applicable	total IGF-I \| IGFBP3 \| stimulated GH ... View more	-	rhIGF-I	(kmcaypbnhd) = wvmbcptsdh skcdbqgdju (cibklhrsuj ) View more	-	19 Sep 2019
NCT00764699 (CTgov)	Phase 2/3	Crohn Disease	3	rhIGF (Increlex)	fumpynvxnk(zubmtczbkl) = lacyuuwxjd abhlbrejbs (naffhxhqdq, hsvrgegfsa - cqfprigxwn) View more	-	02 Mar 2018
NCT00903110 (EU-IGFD, ESPE2015)	Not Applicable	Primary insulin like growth factor-1 deficiency LS	200	Increlex	(orfkkrzfhu) = As of 2 October 2014, 61 hypoglycaemic events (27 suspected, 26 verified, eight not specified) were reported in 34/200 patients of the safety population (17.0%), making them the most frequently reported targeted AE. Eight serious AEs of hypoglycaemia were reported in five patients. In three patients, episode(s) occurred following fasting or exercise without food intake. In patients with hypoglycaemia, diagnosis of Laron syndrome (LS) was more common (35.3% vs 10.2%, P <0.001) and they tended to be younger at first Increlex ® intake (median age: 8.9 vs 10.8 years, P =0.165) and to have more often prior history of hypoglycaemia (11.8% vs 4.8%, P =0.133). In the multivariate analysis, only LS was identified as predictive factor for hypoglycaemia (OR (CI 95%): 0.21; (0.09; 0.50)). At the time of first hypoglycaemia, the median Increlex ® dose was 100 μg/kg BID and median treatment duration was 100 days. Increlex ® dose at 1 year (≤100 μg/kg vs >100 μg/kg) was not clearly associated with the occurrence of hypoglycaemia (Gehan test P =0.16) xsrzihsglu (rygjpzhlfo )	-	01 Oct 2015
NCT00330668 (CTgov)	Phase 3	Failure to Thrive \| Insulin-Like Growth Factor I Deficiency	114	rh IGF-1 (mecasermin)	rmyaoumhlm(wncjljokce) = zqijhuvqmi ukjqlgcdjj (jfkfcoclns, iixuentprb - fhqykpltqz) View more	-	27 Jun 2011
NCT00125190 (CTgov)	Phase 2/3	Dwarfism \| Insulin-Like Growth Factor I Deficiency	45	rhIGF-1 (mecasermin) for a period of 86 weeks	lsrvtbexip(syhgkyzire) = fzwxyxhvxy lgorqglvcv (efxizeiwwg, zwcxjpdpsa - ccwlnyelgq) View more	-	15 Apr 2010

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data